Avalo Therapeutics Inc (AVTX)

NASDAQ
3.620
+0.370(+11.38%)
  • Volume:
    13,661
  • Day's Range:
    3.270 - 3.750
  • 52 wk Range:
    2.423 - 29.400

AVTX Overview

Prev. Close
3.25
Day's Range
3.27-3.75
Revenue
6.09M
Open
3.32
52 wk Range
2.423-29.4
EPS
-9.55
Volume
13,661
Market Cap
34.08M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
42,438
P/E Ratio
-0.438
Beta
1.29
1-Year Change
-85.9%
Shares Outstanding
9,414,105
Next Earnings Date
Nov 08, 2022
What is your sentiment on Avalo Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Avalo Therapeutics Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Avalo Therapeutics Inc Analysis

Avalo Therapeutics Inc Company Profile

Avalo Therapeutics Inc Company Profile

Employees
43

Avalo Therapeutics, Inc. is a clinical-stage precision medicine company. The Company discovers, develops, and commercializes therapeutics for patients with unmet clinical needs in immunology and rare genetic diseases. Its clinical-stage pipeline includes AVTX-002, AVTX-007, and AVTX-800 programs. AVTX-002 is an Anti-LIGHT monoclonal antibody for treatment of non-eosinophilic asthma, moderate to severe inflammatory bowel disease, and COVID-19 acute respiratory distress syndromes. AVTX-007 is a fully human monoclonal antibody for the treatment of Still’s Disease, including adult-onset Still’s disease (AOSD) and systemic juvenile jdiopathic Arthritis (SJIA). Its AVTX-800 programs include AVTX-801 and AVTX-803, AVTX-802, AVTX-008, and AVTX-006. VTX-801 and AVTX-803 are monosaccharide therapies for the treatment of congenital disorders of glycosylation (CDGs). AVTX-006 is a dual mTORc1/c2 small molecule inhibitor for the treatment of complex lymphatic malformations.

Read More

Analyst Price Target

Average43.500 (+1101.66% Upside)
High84
Low9
Price3.62
No. of Analysts4
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyBuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
  • any opinion for CERC ? will go up to 5$ soon ?
    1
    • any precious idea what will happen with CERC please ?
      1
      • They Will have a virtuale encounter with potential investor on 06/ 01/2022, After tomorrow. They probably Will talk about two new drugs they presented FDA , the result of their studies and FDA position. If everithing Is positive the stock might grow .
        0
      • Tu che ne pensi sarà positivo o no?
        0
    • is it worths to entry right now ? what do you think folks ?
      0
      • $5 stock by November 15th, 2017
        0
        • Possibly more, if they announce good news in conjunction with the positive news they announced earlier this year with CERC-301. FDA already intends to fast track the approval for the MDD drug.
          0